Importance of adequate initial antimicrobial therapy

Chemotherapy

Volumn 51, Issue 4, 2005, Pages 171-176

  Ramphal, Reuben ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antimicrobial therapy; Infection

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG USE; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; INCIDENCE; MEDICAL LITERATURE; MEDICATION ERROR; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; TREATMENT OUTCOME;

EID: 26044452415     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086574     Document Type: Review

References (30)

1. Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents 2002;19:261-268.
2. Harbarth S. Garbino J, Pugin J. et al: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115:529-535.
3. Leibovici L, Paul M, Poznanski O, et al: Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-1133.
4. Behrendt G, Schneider S, Brodt HR, et al: Influence of antimicrobial treatment on mortality in septicemia. J Chemother 1999;11:179-186.
5. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
6. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-155.
7. Blot S, Vandewoude K, De Bacquer D, Colardyn F: Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: Clinical outcome and length of hospitalization. Clin Infect Dis 2002;34:1600-1606.
8. Iregui M, Ward S, Sherman G, et al: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;22:262-268.
9. Dupont H, Montravers P, Gauzit R, Veber B, Pouriat JL, Martin C, Club d'Infectiologie en Anesthesie-Reanimation: Outcome of postoperative pneumonia in the Eole study. Intensive Care Med 2003;29:179-188.
10. Valles J, Rello J, Ochagavia A, et al: Community-acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003;123:1615-1624.
11. Zaragoza R, Artero A, Camarena JJ, et al: The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003;9:412-418.
12. MacArthur RD, Miller M, Albertson T, et al: Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS trial. Clin Infect Dis 2004;38:284-288.
13. Clec'h C, Timsit JF, De Lassence A, et al: Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: Influence of disease severity. Intensive Care Med 2004;30:1327-1333.
14. Heyland DK, Cook DJ, Griffith L, et al: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999;59:1249-1256.
15. Thylefors JD, Harbarth S, Pittet D: Increasing bacteremia due to coagulase-negative staphylococci: Fiction or reality. Infect Control Hosp Epidemiol 1998;8:581-589.
16. Pelz RK, Lipsett PA, Swoboda SM, et al: Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: Attributable costs and outcomes. Intensive Care Med 2002;28:692-697.
17. Kang CI, Kim SH, Kim HB, et al: Pseudomonas aeruginosa bacteremia: Risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745-751.
18. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003;36:1418-1423.
19. Wong-Beringer A, Hindler J, Loeloff M, et al: Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135-146.
20. Kim YK, Pai H, Lee HJ, et al: Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: Epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481-1491.
21. Du B, Long Y, Liu H, et al: Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: Risk factors and clinical outcome. Intensive Care Med 2002;28:1718-1723.
22. Paterson DL, Ko WC, Von Gottberg A, et al: Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-37.
23. Houck PM, Bratzler DW, Nsa W, et al: Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-644.
24. Jaccard C, Troillet N, Harbarth S, et al: Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42:2966-2977.
25. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH: Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-1382.
26. Fink MP, Snydman DR, Niederman MS, et al: Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994;38:547-557.
27. Pechere JC, Vladoianu IR: Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother 1992;29:563-573.
28. Chow JW, Fine MJ, Shlaes DM, et al: Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-590.
29. Schwaber MJ, Graham CS, Sands BE, et al: Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporinresistant Enterobacter species. Antimicrob Agents Chemother 2003;47:1882-1886.
30. Kollef MH, Ward S, Sherman G, et al: Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000;28:3456-3464.